First FDA approved treatment for PROS conditions
The U.S. Food and Drug Administration granted accelerated approval for Novartis’ PI3K inhibitor Vijoice (alpelisib) for use in PIK3CA-related overgrowth spectrum (PROS), including M-CM / MCAP patients. Learn more »